Irigoyen O, Rizzolo P V, Thomas Y, Rogozinski L, Chess L
Adv Exp Med Biol. 1984;172:383-404. doi: 10.1007/978-1-4615-9376-8_22.
Human T-cell hybrids with helper activity were obtained after fusion of phytohemagglutinin-activated normal human T cells with a 6-thioguanine-resistant, aminopterin-sensitive human T-cell line. This mutant line, designated CEM-T15, was derived from the human T-cell line CEM after mutagenesis with ethyl methanesulfonate. The polyethylene glycol induced fusion and the selection in hypoxanthine- aminopeterin -thymidine medium were performed by modification of standard somatic cell hybridization techniques. After fusion, the strategy for selecting hybrids consisted in screening growing cultures for the presence of cells expressing the OKT3 cell surface differentiation antigen. OKT3 was chosen because it is present in 85-95% of normal human T cells but absent from CEM-T15 cells. Thus, OKT3+ cells growing 5-7 weeks after fusion most likely represented hybrids between normal T cells (OKT3+) and continuously growing CEM-T15 cells (OKT3-). Several of the hybrids were tested for their capacity to promote pokeweed mitogen-induced antibody production by B cells. These experiments demonstrated that many of the hybrids had helper activity. Periodical testing of these uncloned hybrids for helper activity revealed functional instability, with most of the hybrids losing helper activity after 20 weeks of continuous culture. However, early and repeated cloning of the same hybrids resulted in a series of hybrid clones with helper activity still present more than 8 months after fusion. In more recent fusions, we have demonstrated that human helper hybrids producing helper factor(s) can also be obtained. These and similar hybrids with different functions will be of considerable importance in further studies of the immunobiology of human T lymphocytes.
用植物血凝素激活的正常人T细胞与一株对6-硫鸟嘌呤耐药、对氨基蝶呤敏感的人T细胞系融合后,获得了具有辅助活性的人T细胞杂交体。这个突变细胞系命名为CEM-T15,是用甲磺酸乙酯诱变后从人T细胞系CEM衍生而来的。通过改进标准的体细胞杂交技术进行聚乙二醇诱导融合以及在次黄嘌呤-氨基蝶呤-胸腺嘧啶核苷培养基中进行筛选。融合后,选择杂交体的策略是在生长的培养物中筛选表达OKT3细胞表面分化抗原的细胞。选择OKT3是因为它存在于85%-95%的正常人T细胞中,但在CEM-T15细胞中不存在。因此,融合后5-7周生长的OKT3+细胞很可能代表正常T细胞(OKT3+)与持续生长的CEM-T15细胞(OKT3-)之间的杂交体。对几个杂交体促进B细胞由商陆丝裂原诱导的抗体产生的能力进行了检测。这些实验表明许多杂交体具有辅助活性。对这些未克隆的杂交体的辅助活性进行定期检测发现其功能不稳定,大多数杂交体在连续培养20周后失去辅助活性。然而,对同一杂交体进行早期和反复克隆,得到了一系列在融合后8个月以上仍具有辅助活性的杂交克隆。在最近的融合实验中,我们证明了也可以获得产生辅助因子的人辅助杂交体。这些以及具有不同功能的类似杂交体在人类T淋巴细胞免疫生物学的进一步研究中将具有相当重要的意义。